{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=38",
    "query": {
      "intervention": "Combination Agent",
      "page": 38
    },
    "page_size": 10
  },
  "pagination": {
    "page": 38,
    "page_size": 10,
    "total_count": 5568,
    "total_pages": 557,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=39&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Agent&page=37&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T17:58:02.488Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03506412",
      "title": "Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Heart Failure With Preserved Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "Entresto™ 49Mg-51 mg tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2018-06-25",
      "completion_date": "2021-03-23",
      "has_results": true,
      "last_update_posted_date": "2022-02-04",
      "last_synced_at": "2026-11-15T17:58:02.488Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03506412"
    },
    {
      "nct_id": "NCT04553692",
      "title": "Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Colorectal Cancer",
        "Non Hodgkin Lymphoma",
        "Sarcoma",
        "Chondrosarcoma",
        "Small Lymphocytic Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Aplitabart (IGM-8444)",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab (and approved biosimilars)",
          "type": "DRUG"
        },
        {
          "name": "Birinapant",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IGM Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 272,
      "start_date": "2020-09-23",
      "completion_date": "2025-01-20",
      "has_results": false,
      "last_update_posted_date": "2025-03-28",
      "last_synced_at": "2026-11-15T17:58:02.488Z",
      "location_count": 37,
      "location_summary": "Phoenix, Arizona • Duarte, California • Los Alamitos, California + 29 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04553692"
    },
    {
      "nct_id": "NCT04124939",
      "title": "Is 10 Injections of Bladder Botox Less Painful Than 20 Injections?",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Overactive Bladder"
      ],
      "interventions": [
        {
          "name": "OnabotulinumtoxinA 100 Units",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 90 Years · Female only"
      },
      "enrollment_count": 41,
      "start_date": "2019-11-10",
      "completion_date": "2023-02-23",
      "has_results": true,
      "last_update_posted_date": "2024-04-17",
      "last_synced_at": "2026-11-15T17:58:02.488Z",
      "location_count": 2,
      "location_summary": "Greensboro, North Carolina • Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Greensboro",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04124939"
    },
    {
      "nct_id": "NCT00551707",
      "title": "Multicenter Study to Evaluate CRx-102 vs. Each of Its Components to Treat Active Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "CRx-102 (2.7/180)",
          "type": "DRUG"
        },
        {
          "name": "prednisolone",
          "type": "DRUG"
        },
        {
          "name": "dipyridamole",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "CRx-102 (2.7/360)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zalicus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2007-10",
      "completion_date": "2009-01",
      "has_results": true,
      "last_update_posted_date": "2014-04-29",
      "last_synced_at": "2026-11-15T17:58:02.488Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00551707"
    },
    {
      "nct_id": "NCT05464329",
      "title": "Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Large B-cell Lymphoma",
        "High-grade B-cell Lymphoma",
        "Transformed B-Cell Lymphoma",
        "Follicular Lymphoma Grade 3B"
      ],
      "interventions": [
        {
          "name": "Mosunetuzumab",
          "type": "DRUG"
        },
        {
          "name": "DHAX",
          "type": "DRUG"
        },
        {
          "name": "ICE",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Washington University School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2023-01-03",
      "completion_date": "2029-10-16",
      "has_results": false,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-11-15T17:58:02.488Z",
      "location_count": 1,
      "location_summary": "St Louis, Missouri",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05464329"
    },
    {
      "nct_id": "NCT01837667",
      "title": "Phase I Study of LB-100 With Docetaxel in Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tumors",
        "Neoplasms",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "LB-100 for Injection",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lixte Biotechnology Holdings, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2013-02",
      "completion_date": "2016-09",
      "has_results": false,
      "last_update_posted_date": "2017-01-24",
      "last_synced_at": "2026-11-15T17:58:02.488Z",
      "location_count": 5,
      "location_summary": "Duarte, California • Rochester, Minnesota • Las Vegas, Nevada + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Tyler",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01837667"
    },
    {
      "nct_id": "NCT02616029",
      "title": "Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "E/C/F/TAF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2015-12-17",
      "completion_date": "2019-07-11",
      "has_results": true,
      "last_update_posted_date": "2020-07-23",
      "last_synced_at": "2026-11-15T17:58:02.488Z",
      "location_count": 3,
      "location_summary": "Ft. Pierce, Florida • Orlando, Florida • West Palm Beach, Florida",
      "locations": [
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02616029"
    },
    {
      "nct_id": "NCT00624195",
      "title": "Clinical Trial of CNS-targeted HAART (CIT2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "FDA Approved Antiretroviral Therapy (see list below)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2007-03",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2014-04-23",
      "last_synced_at": "2026-11-15T17:58:02.488Z",
      "location_count": 5,
      "location_summary": "San Diego, California • San Francisco, California • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00624195"
    },
    {
      "nct_id": "NCT01418365",
      "title": "Metronidazole Drug Interaction Study With MMX® Mesalazine/Mesalamine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Metronidazole + MMX Mesalazine/mesalamine placebo",
          "type": "DRUG"
        },
        {
          "name": "Metronidazole + MMX Mesalazine/mesalamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 30,
      "start_date": "2011-08-22",
      "completion_date": "2011-10-05",
      "has_results": true,
      "last_update_posted_date": "2021-06-09",
      "last_synced_at": "2026-11-15T17:58:02.488Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01418365"
    },
    {
      "nct_id": "NCT03909165",
      "title": "Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Neuromuscular Blockade"
      ],
      "interventions": [
        {
          "name": "Sugammadex 2 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Sugammadex 4 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Neostigmine + Glycopyrrolate",
          "type": "DRUG"
        },
        {
          "name": "Neostigmine + Atropine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "2 Years",
        "sex": "ALL",
        "summary": "1 Day to 2 Years"
      },
      "enrollment_count": 145,
      "start_date": "2019-07-23",
      "completion_date": "2023-09-21",
      "has_results": true,
      "last_update_posted_date": "2025-07-25",
      "last_synced_at": "2026-11-15T17:58:02.488Z",
      "location_count": 7,
      "location_summary": "Palo Alto, California • Miami, Florida • Oklahoma City, Oklahoma + 4 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03909165"
    }
  ]
}